We updated the design of this site on September 25th. Learn more.

The Impact of Lorazepam on Cognition in APOE e4 Carriers

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00586430

First Posted: January 4, 2008

Last Update Posted: January 4, 2008

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

National Institute of Mental Health (NIMH)

Information provided by:

Mayo Clinic

Purpose

We expect the results of this pilot study to justify a larger study that follows people to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam (a widely used anti-anxiety medication) could predict an individual's risk of developing AD. We plan to compare cognitively normal people who possess a common gene that increases risk for AD— the apolipoprotein E (APOE) e4 allele—to individuals without this gene. We hypothesize that a single 2 mg dose of lorazepam will cause more cognitive impairment in carriers of the APOE e4 allele than in noncarriers, and that the carriers will recover more slowly from these impairments than noncarriers.

Condition	Intervention
Alzheimer's Disease	Drug: lorazepam Drug: placebo


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Screening
Official Title:	The Impact of Lorazepam on Cognition in APOE e4 Carriers

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Drug Information available for: Lorazepam

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

Groton Maze Learning Task [ Time Frame: baseline, 2.5 hours and 5 hours ]

Secondary Outcome Measures:

Auditory Verbal Learning Test [ Time Frame: baseline, 2.5 hours and 5 hours ]
1-back test [ Time Frame: baseline, 2.5 hours and 5 hours ]


Enrollment:	36
Study Start Date:	December 2005
Study Completion Date:	July 2007
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 single 2 mg dose of lorazepam	Drug: lorazepam single 2 mg dose of lorazepam Other Name: Ativan
Placebo Comparator: 2 single dose of placebo	Drug: placebo single dose of placebo

Detailed Description:

We aim to compare measures of memory and information processing speed at 2.5 hours and 5 hours after the administration of a 2 mg dose of lorazepam or placebo in cognitively normal, 50-65 year old APOE e4 carriers and noncarriers, and determine the differential impact of lorazepam on cognition at each time point. Twenty carriers and 20 noncarriers matched for age, sex, and education will be drawn from a database of persons who have already undergone genotyping for an ongoing study at the Mayo Clinic, excluding people with evidence of depression or cognitive impairment and other medical, neurological or psychiatric conditions. Using a double blind, crossover design, subjects will receive either placebo or a 2 mg dose of lorazepam after baseline testing. Equivalent tests will be repeated 2.5 and 5 hours post challenge. The data analysis will compare APOE e4 carriers to noncarriers.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	50 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

a score of at least 28 on the MMSE
a score of less than 10 points on the HAM-D-17
age 50-65
genotype APOE e3/e4 or APOE e4 non-carriers
cognitively normal

Exclusion Criteria:

significant medical, psychiatric, or neurological illnesses
use of benzodiazepines within the previous four weeks
currently using sedating antihistamines

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00586430

Locations


United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259

Sponsors and Collaborators

Mayo Clinic

National Institute of Mental Health (NIMH)

Investigators


Principal Investigator:	Cynthia M Stonnington, M.D.	Mayo Clinic

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers. J Clin Psychiatry. 2009 Oct;70(10):1379-84. doi: 10.4088/JCP.08m04593. Epub 2009 Jun 30.


Responsible Party:	Cynthia Stonnington, M.D., Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00586430 History of Changes
Other Study ID Numbers:	929-05
First Submitted:	December 21, 2007
First Posted:	January 4, 2008
Last Update Posted:	January 4, 2008
Last Verified:	December 2007

Keywords provided by Mayo Clinic:


apolipoprotein E e4 Alzheimer's disease somnolence Early detection

Additional relevant MeSH terms:


Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Lorazepam Anticonvulsants Antiemetics Autonomic Agents	Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Hypnotics and Sedatives Central Nervous System Depressants Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action

To Top